Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway.

BACKGROUND: Elevated level of interleukin-8 (IL-8) promotes hepatocellular carcinoma (HCC) development and contributes to poor prognosis. Previously, we have proved that Dicer inhibits HCC progression. In this study, we evaluated the potential interaction between IL-8 and Dicer as well as their infl...

Descripción completa

Detalles Bibliográficos
Publicado en:Clinical Medicine Insights: Oncology Vol. 17; pp. 1 - 8
Autores principales: Xin Han, Jianhua Wu, Ziyue Sha, Ruixue Lai, Jianfei Shi, Lili Mi, Fei Yin, Zhanjun Guo
Formato: pictorial research tables/charts Journal Article
Publicado: Sage Publications Inc. Jan-Dec2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175226904&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 175226904
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11795549
        B3KT
      jtl: Clinical Medicine Insights: Oncology
      issn: 11795549
      maglogo: Y
    pubinfo:
      dt: Jan-Dec2023
      vid: 17
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        175226904
        175226904
        175226904
        10.1177/11795549231161212
        175226904
      ppf: 1
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway.
      aug:
        au:
          Xin Han
          Jianhua Wu
          Ziyue Sha
          Ruixue Lai
          Jianfei Shi
          Lili Mi
          Fei Yin
          Zhanjun Guo
        affil: Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, PR China
      sug:
        subj:
          Esterases
          Interleukins Blood
          Carcinoma, Hepatocellular Drug Therapy
          Carcinoma, Hepatocellular Prognosis
          Drug Interactions Evaluation
          Animal Studies
          Mice
          Funding Source
          Gene Expression
          Wound Healing Physiology
          Flow Cytometry
          Descriptive Statistics
          Immunoassay
          Cell Proliferation
      ab: BACKGROUND: Elevated level of interleukin-8 (IL-8) promotes hepatocellular carcinoma (HCC) development and contributes to poor prognosis. Previously, we have proved that Dicer inhibits HCC progression. In this study, we evaluated the potential interaction between IL-8 and Dicer as well as their influence on HCC. METHODS: Hepatocellular carcinoma cells of SMMC-7721 were divided into 2 groups for subsequent analysis: pCMV-Dicer group for Dicer-overexpressing lentivirus transfected cells (pCMV-Dicer cells) and pCMV-NC group for empty lentivirus transfected cells (pCMV-NC cells). Cell Counting kit-8 (CCK8), wound healing, and transwell were used to evaluate the inhibitory effect of Dicer overexpression on proliferation, migration, and invasion of HCC cells. The level of IL-8 was measured by flow cytometry bead-based immunoassays. Male nude BALB/c mice injected with pCMV-Dicer or pCMV-NC cell suspensions was used for transplant of HCC tumor. RESULTS: We found that the secretion of IL-8 was reduced in the medium of pCMV-Dicer cells (P = .027). Recombinant human IL-8 (rhIL-8) reversed the inhibitory effect of Dicer on proliferation (P < .01), migration (P = .003), and invasion (P = .001), whereas IL-8 inhibitor of reparixin enhanced inhibitory effect of Dicer on proliferation (P < .05), migration (P = .008), and invasion (P = .000). Lenvatinib downregulated the IL-8 level of HCC cells (P = .000) as well as promote Dicer-induced inhibition for HCC cells referring to proliferation (P < .05), migration (P = .000), and invasion (P = .000). Animal experiments also demonstrated that Dicer cooperated with lenvatinib to inhibit the growth of HCC tumors (P < .05). CONCLUSIONS: Dicer cooperated with lenvatinib to inhibit HCC growth via downregulating IL-8, and Dicer displayed its potential capability to enhance the anti-tumor effect of lenvatinib.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N